The Breast Cancer Resistance Protein (BCRP/ABCG2) Affects Pharmacokinetics, Hepatobiliary Excretion, and Milk Secretion of the Antibiotic Nitrofurantoin

Gracia Merino, Johan W. Jonker, Els Wagenaar, Antonius E. van Herwaarden, and Alfred H. Schinkel

Division of Experimental Therapy, The Netherlands Cancer Institute, Amsterdam, The Netherlands

Received December 17, 2004; accepted February 11, 2005

ABSTRACT

Nitrofurantoin is a commonly used urinary tract antibiotic prescribed to lactating women. It is actively transported into human and rat milk by an unknown mechanism. Our group has demonstrated an important role of the breast cancer resistance protein (BCRP/ABCG2) in the secretion of xenotoxins into the milk. This ATP-binding cassette drug efflux transporter extrudes xenotoxins from cells in intestine, liver, mammary gland, and other organs, affecting the pharmacological and toxicological behavior of many compounds. We investigated whether Bcrp1 is involved in the pharmacokinetic profile of nitrofurantoin and its active secretion into the milk. Using polarized cell lines, we found that nitrofurantoin is efficiently transported by murine Bcrp1 and human BCRP. After oral administration of 10 mg/kg nitrofurantoin, the area under the plasma concentration-time curve in Bcrp1 knockout mice was almost 4-fold higher than in wild-type mice (148.8 ± 30.4 versus 37.5 ± 6.8 min · µg/ml); and after i.v. administration (5 mg/kg), 2-fold higher (139.2 ± 22.0 versus 73.9 ± 9.0 min · µg/ml). Hepatobiliary excretion of nitrofurantoin was almost abolished in Bcrp1 knockout mice (9.6 ± 3.2 versus 0.2 ± 0.1% in wild-type and Bcrp1 knockout mice, respectively). The milk-to-plasma ratio of nitrofurantoin was almost 80 times higher in wild-type compared with Bcrp1 knockout lactating female mice (45.7 ± 16.2 versus 0.6 ± 0.1). Nitrofurantoin elimination via milk was quantitatively even higher than hepatobiliary elimination. We conclude that Bcrp1 is an important determinant for the bioavailability of nitrofurantoin and the main mechanism involved in its hepatobiliary excretion and secretion into the milk.

Nitrofurantoin (1-[(5-nitro-2-furanyl)methylene]amino-2,4-imidazolidinedione) is a nitrofuran-derivative antibacterial agent widely used in human and veterinary medicine. In humans, it is mainly used to treat urinary tract infections, which are among the most common bacterial infections. Patients receiving nitrofurantoin may have rare but serious side effects such as chronic liver disease, cholestatic hepatitis, or hemolytic anemia in glucose-6-phosphate dehydrogenase-deficient patients (Gerk et al., 2001a). Moreover, nitrofurantoin has been shown to be mutagenic and carcinogenic in animal models (Kari et al., 1997). Further knowledge about the factors affecting the pharmacokinetics of nitrofurantoin is therefore of clinical and toxicological importance.

Nitrofurantoin is also prescribed to lactating women. Adverse transfer of drugs administered to the mother to milk is always a matter of concern in view of possible adverse effects in the infant. Nitrofurantoin is an inexpensive antibiotic that is often used in developing countries where formula feeding is not an alternative for breastfeeding (Kari et al., 1997). However, preliminary results from a continuous breeding study with mice revealed that chronic nitrofurantoin treatment of lactating mice resulted in decreased pup growth rate (Kari et al., 1997).

It has been demonstrated that nitrofurantoin is actively transported into human and rat milk, reaching milk-to-serum concentration ratios of 20 and 100 times those predicted by diffusion, respectively (Gerk et al., 2001a,b). Furthermore, active, saturable transport of nitrofurantoin across a murine cell culture model of lactation has been demonstrated (Toddywalla et al., 1997). However, the active transport mechanism involved has not been identified yet.
Breast cancer resistance protein (BCRP/ABCG2) is a member of the ATP-binding cassette (ABC) family of transporters (Doyle et al., 1998; Allen and Schinkel, 2002) that affects the pharmacological and toxicological behavior of many drugs and toxins. This 655-amino acid transmembrane protein transports a range of anticancer drugs, dietary compounds, and food carcinogens such as PhIP (Jonker et al., 2002; van Herwaarden et al., 2003). It actively extrudes its substrates from cells, and it is localized in the apical membranes of intestinal and placental epithelia, in the biliary canalicular membrane of hepatocytes, and in the blood-brain barrier. Several in vivo studies indicated that Bcrp1 limits the oral bioavailability and fetal and brain penetration and mediates the hepatobiliary excretion and intestinal elimination of its (drug) substrates (Jonker et al., 2000; van Herwaarden et al., 2003; Cisternino et al., 2004).

Our group has recently demonstrated expression of mouse Bcrp1 and human BCRP in the lactating mammary gland and established an important role of Bcrp1 in the active secretion and concentration of several drugs and carcinogenic xenotoxins into milk (Jonker et al., 2005). Because nitrofurantoin is actively secreted into the milk (Gerk et al., 2001a,b), Bcrp1 is a good candidate for the mechanism involved in this phenomenon. In addition, there are indications for involvement of Bcrp1 in the renal excretion of some of its substrates (Mizuno et al., 2004). Because nitrofurantoin is extensively excreted into the urine of humans and is used to treat urinary infections, it was further interesting to investigate the role of Bcrp1 in this excretory pathway for nitrofurantoin.

In this study, we have demonstrated that nitrofurantoin is transported by Bcrp1/BCRP and that Bcrp1 is involved in the pharmacokinetic profile of nitrofurantoin and its active secretion into the milk, applying in vitro and in vivo studies using Bcrp1 knockout mice.

Materials and Methods

Animals. Mice were housed and handled according to institutional guidelines complying with Dutch legislation. Animals used were male or lactating female Bcrp1−/− and wild-type mice, all of >99% FVB genetic background between 9 and 14 weeks of age. Animals were kept in a temperature-controlled environment with a 12-h light/dark cycle and received a standard diet (AM-Ⅱ; Hope Farms, Woerden, The Netherlands) and acidified water ad libitum.

Chemicals. Nitrofurantoin, furazolidone, and xylazine were from Sigma-Aldrich (St. Louis, MO); [3H]inulin was from Amersham Biosciences UK, Ltd. (Little Chalfont, Buckinghamshire, UK); ketamine (Ketanest-S) was from Parke-Davis (Hoofddorp, The Netherlands); oxytocin (Sintocinon) was from Novartis (Basel, Switzerland); methoxyflurane (Metofane) was from Medical Developments Australia Pty, Ltd. (Springvale, VIC, Australia); and Ko143 was described previously (Allen et al., 2002). All other compounds used were agent grade.

Cells and Tissue Culture. The polarized canine kidney cell line MDCK-II was used in the transport assays. Human MDR1-, MRP2-, BCRP-, and murine Bcrp1-transduced MDCK-II subclones were described previously (Evers et al., 1998; Jonker et al., 2000; Pavek et al., 2005). The MDCK-II cells and transduced subclones were cultured in Dulbecco’s modified Eagle’s medium supplied with Glutamax (Invitrogen, Carlsbad, CA) and supplemented with 50 units/ml penicillin, 50 μg/ml streptomycin, and 10% (v/v) fetal calf serum (Invitrogen) at 37°C in the presence of 5% CO₂. The cells were trypsinized every 3 to 4 days for subculturing.

Transport Assays. Transport assays were carried out as described previously (Huisman et al., 2001), with minor modifications. Cells were seeded on microporous membrane filters (3.0-μm pore size, 24-mm diameter; Transwell 3414; Corning Glassworks, Corning, NY) at a density of 1.0 × 10⁶ cells per well. Cells were grown for 3 days, and medium was replaced every day. Two hours before the start of the experiment, medium at both the apical and basolateral side of the monolayer was replaced with 2 ml of OptiMEM medium (Invitrogen), without serum, either with or without 5 μM Ko143. The experiment was started at t = 0 by replacing the medium in either the apical or basolateral compartment with fresh OptiMEM medium, either with or without 5 μM Ko143 and containing 10 μM nitrofurantoin and 192 nM [3H]inulin. Cells were incubated at 37°C in 5% CO₂ and 50-μl aliquots were taken at t = 2 and 4 h and stored at −20°C until the time of analysis. The presence of nitrofurantoin in the opposite compartment was measured by HPLC as described below and presented as the fraction of total nitrofurantoin added at the beginning of the experiment. The tightness of the monolayer was measured by monitoring the paracellular flux of [3H]inulin to the opposite compartment, which had to remain <1.5% of the total radioactivity per hour.

Pharmacokinetic Experiments. For oral administration of 10 mg/kg nitrofurantoin, 3.5 μl of drug solution [appropriate concentration in 50% (v/v) ethanol and 50% (v/v) polyethylene glycol 400]/g body weight was dosed by gavage into the stomach. For i.v. administration of 5 mg/kg nitrofurantoin, 5 μl of drug solution [appropriate concentration in 10% (v/v) ethanol, 40% (v/v) polyethylene glycol 400, and 50% phosphate-buffered saline]/g body weight were injected into the tail of mice lightly anesthetized with methoxyflurane. Animals were sacrified by cardiac puncture after anesthesia with methoxyflurane, and blood was collected. Heparinized blood samples were centrifuged immediately at 3000g for 15 min, and plasma was collected and stored at −20°C until the time of HPLC analysis. Three to five animals were used for each time point.

Gall Bladder Cannulation Experiments. For gall bladder cannulation experiments, mice were anesthetized with a combination of 100 mg/kg ketamine and 6.7 mg/kg xylazine. The gall bladder was cannulated as described previously (van Herwaarden et al., 2003). Bile was collected in 15-min fractions for 60 min after injection of 5 mg/kg nitrofurantoin into the tail vein. At the end of the experiment, blood was collected by cardiac puncture. Bile and plasma were stored at −20°C until the time of HPLC analysis. Five to six animals were used for each group.

Metabolic Cage Experiment. Mice were housed in a Rucow (Valkenswaard, The Netherlands) type M1 metabolic cage. They were allowed to get accustomed to the cages for 2 days, before receiving 5 mg/kg nitrofurantoin injected into the tail vein. At the indicated time, 50 μl of milk was collected from the fourth and fifth pairs of mammary glands by gentle vacuum suction. Immediately after milk collection, animals were sacrificed by cardiac puncture after anesthesia with methoxyflurane, and heparinized blood was collected. Milk and plasma were stored at −20°C until the time of HPLC analysis. Four animals were used for each group.

Milk Secretion Experiments. For milk experiments, pups approximately 10 days old were separated from the mother approximately 4 h before starting the experiment. To stimulate milk secretion, oxytocin (200 μl of 1 IU/ml solution) was administered subcutaneously to lactating dams. Nitrofurantoin (5 mg/kg) was injected into the tail vein at 30 min before milk was collected. At the indicated time, 50 μl of milk was collected from the fourth and fifth pairs of mammary glands by gentle vacuum suction. Immediately after milk collection, animals were sacrificed by cardiac puncture after anesthesia with methoxyflurane, and heparinized blood was collected. Milk and plasma were stored at −20°C until the time of HPLC analysis. Three to four animals were used for each group.

HPLC Analysis. The conditions for HPLC analysis of nitrofurantoin were modified based on a previously published method (Gerk et al., 2001b). The methodology for the extraction of the samples was based on the use of an organic solvent, such as cold methanol, for
protein precipitation (Bollag and Edelstein, 1991; Prieto et al., 2003).
Samples were thawed and kept protected from light in brown Ep
pendorf tubes during preparation. To each 50-μl aliquot of sample, 5 μl of a 12.5 μg/ml furazolidone solution was added as an internal
standard in a 1.5-ml reaction tube. The mixture was vortexed vigorously,
and 50 μl of methanol at −20°C was added for protein precipi
titation. Extraction was carried out by vigorously shaking the reac
tion tube for 60 s and incubating at −30°C for 15 min. The organic
water phases were separated by centrifugation at 16,000g for 5
min at 4°C, and 50 μl of the organic phase was injected into the
HPLC system. Samples from the transport assays were not pro
cessed, and 100 μl of the culture media was directly injected into the
HPLC system. The system consisted of a Waters 610 pump, a Waters
717plus autosampler, and an UV detector (model UV2000; Thermo
Electron Corporation, Waltham, MA). Separation was performed at
30°C on a reversed-phase column (Nucleosil 120 C18, 10-μm particle
size, 250 × 4 mm), preceded by a precolumn cartridge (3.9 × 20 mm)
packed with the same packing material. The composition of the
mobile phase was 25 mM potassium phosphate buffer, pH 3/aceto
nitrile (75:25). The flow rate of the mobile phase was set to 1.2
ml/min. UV absorbance was measured at 366 nm. Peak area ratios
(nitrofurantoin/furazolidone) were used for comparison with the
standard curve. The integration was performed using the software Millennium²⁰
(Waters, Etten-Leur, The Netherlands). Standard
samples in the appropriate drug-free matrix were prepared yielding
a concentration range from 0.125 to 8 μg/ml.

Pharmacokinetic Calculations and Statistical Analysis. The
two-sided unpaired Student’s t test was used throughout to assess the
statistical significance of differences between the two sets of data.
Results are presented as the means ± standard deviations. Differences
were considered to be statistically significant when p < 0.05. AUC from
time = 0 to the last sampling point was calculated by the linear trap
pezoidal rule, and oral availability was determined by (AUCp.o./dose
p.o.)/AUCp/.dose i.v.), assuming linearity of dose dependence.

Results

In Vitro Transport of Nitrofurantoin. To determine
whether murine Bcrp1 and human BCRP were involved in
nitrofurantoin transport in vitro, we made use of the polar
cized canine kidney cell line MDCK-II and its subclones
transduced with murine Bcrp1 and human BCRP cDNAs.
In addition, human MDR1- and human MRP2-transduced
MDCK-II subclones were also tested for the possible role of
these other ABC transporters in the in vitro transport of
nitrofurantoin. The parental and transduced cell lines were
grown to confluent polarized monolayers on porous mem
brane filters, and vectorial transport of 10 μM nitrofurantoin
across the monolayers was determined. In the MDCK-II pa
rental cell line, nitrofurantoin was consistently translocated somewhat more efficiently in the basolateral direc
tion than in the apical direction (Fig. 1A), suggesting low endogenous basally directed transport. In the Bcrp1- and BCRP-trans
duced MDCK-II cell lines, apically directed translocation was
highly increased and basolaterally directed translocation drastically decreased (Fig. 1, B and D). When the selective
Bcrp1 inhibitor Ko143 was used (Allen et al., 2002), the
Bcrp1/BCRP-mediated transport was completely inhibited
(Fig. 1, C and E), resulting in a vectorial translocation pat
tern equal to that of the MDCK-II parental cell line. In the
MDR1- and MRP2-transduced MDCK-II cell lines, the vector
ial translocation was similar to the MDCK-II parental cell
line (Fig. 1, F and G). These results show highly efficient transport of nitrofurantoin by murine Bcrp1 and human
BCRP, but not by MDR1 or MRP2.

Plasma Pharmacokinetics of Nitrofurantoin in
Bcr1⁻/⁻ and Wild-Type Mice. To assess whether the in
vivo Bcrp1-mediated transport of nitrofurantoin was also
relevant in vivo, we studied nitrofurantoin bioavailability in
Bcrp1⁻/⁻ and wild-type mice. We determined the plasma
concentration of nitrofurantoin as a function of time, after
oral and intravenous administration of nitrofurantoin in both
types of mice (Fig. 2, A and B). After oral administration of 10
mg/kg nitrofurantoin, the AUC of the Bcrp1⁻/⁻ mice was
increased almost 4-fold compared with the wild-type mice
(148.8 ± 30.4 versus 37.5 ± 6.8 min · μg/ml; p < 0.05). For i.v.
administration (5 mg/kg), the AUC of the Bcrp1⁻/⁻ was
almost 2-fold higher compared with the wild-type mice
(139.2 ± 22.0 versus 73.9 ± 9.0 min · μg/ml; p < 0.05). The
calculated oral availability was significantly increased in
Bcrp1⁻/⁻ compared with wild-type mice (53.4 ± 13.8 versus
25.4 ± 9.6%; p < 0.05). Bcrp1 thus seems to be an important
determinant for the oral availability and the elimination
of nitrofurantoin.

Hepatobiliary, Fecal, and Urinary Excretion of Ni
trofurantoin in Bcrp1⁻/⁻ and Wild-Type Mice. To inves
tigate the role of Bcrp1 in the hepatobiliary excretion of
nitrofurantoin, we administered 5 mg/kg nitrofurantoin i.v. to
Bcrp1⁻/⁻ and wild-type mice with a cannulated gall bladder
and ligated common bile duct. Biliary excretion of nitro
furantoin was measured in fractions of 15 min during 1 h.
Bcrp1⁻/⁻ mice showed a dramatically decreased excretion of
nitrofurantoin into bile compared with wild-type mice (Fig. 3).
At 1 h after i.v. administration, the cumulative nitro
furantoin excretion, as percentage of the dose, was 9.7 ± 3.2
versus 0.2 ± 0.1% in wild-type and Bcrp1⁻/⁻ mice, re
spectively. This indicates that more than 98% of the biliary excretion over 1 h can be attributed to Bcrp1 activity. Plasma
contentions at the end of the experiment were 0.13 ± 0.02
and 0.29 ± 0.13 μg/ml (p < 0.05) for wild-type and Bcrp1⁻/⁻ mice, respectively. We conclude that the hepatobiliary excre
tion of nitrofurantoin in mice is virtually completely caused by Bcrp1 activity, because biliary nitrofurantoin was nearly
abolished in Bcrp1⁻/⁻ mice.

To assess the involvement of Bcrp1 in fecal and urinary excretion of nitrofurantoin in nonanesthetized mice, 5 mg/kg
nitrofurantoin was administered i.v. to Bcrp1⁻/⁻ and wild-type mice housed in metabolic cages. Fecal and urinary excre
tion of the unchanged drug was measured. Most of the nitrofurantoin in feces and urine was excreted during the
first 0 to 8 h. The percentage of the dose excreted in feces over the 24 h after administration was negligible (<1%), and there
was no difference between wild-type and Bcrp1⁻/⁻ mice. Regard
ing urinary excretion of nitrofurantoin over the 24 h after administration, there was no significant difference be
 tween wild-type and Bcrp1⁻/⁻ mice (11.3 ± 7.1 versus 7.7 ±
3.7% of dose). This suggests that Bcrp1 does not have a
significant role in the fecal and urinary excretion of nitro
furantoin. Note that enzymatic degradation by body tissues
or intestinal flora probably accounts for the remaining frac
tion of the dose, because nitroreduction by these mechanisms
has a major contribution in the elimination of the drug
(Buzard et al., 1961).

Secretion of Nitrofurantoin into the Milk in
Bcrp1⁻/⁻ and Wild-Type Mice. To test whether Bcrp1
plays a role in the secretion of nitrofurantoin into the milk, 5
mg/kg nitrofurantoin was administered i.v. to lactating
Bcrp\(^{1-/-}\) and wild-type female mice, and 30 min after administration, milk and blood were collected. The data obtained from the analysis of milk and plasma are shown in Fig. 4. Despite the higher plasma level (5-fold), the concentration of nitrofurantoin was substantially lower in the milk of Bcrp\(^{1-/-}\) mice (almost 15-fold). Our data clearly show that nitrofurantoin is actively transported into the milk of mice, because the observed milk-to-plasma ratio for wild-type mice (45.7 ± 16.2) was much higher than the theoretical milk-to-plasma ratio of 0.5 that physicochemical principles would suggest (Kari et al., 1997). In addition, we found that this parameter was almost 80 times higher in wild-type compared with Bcrp\(^{1-/-}\) lactating female mice (45.7 ± 16.2 versus 0.6 ± 0.1).

**Fig. 1.** Transepithelial transport of 10 \(\mu\)M nitrofurantoin in MDCKII (parent) (A), MDCKII-Bcrp1 (B and C), MDCKII-BCRP (D and E), MDCKII-MDR1 (F), and MDCKII-MRP2 (G) monolayers. The experiment was started with the addition of nitrofurantoin to one compartment (basolateral or apical). After 2 and 4 h, the percentage of drug in the opposite compartment was measured by HPLC and plotted. BCRP inhibitor Ko143 (C and E) was present as indicated. Results are the means; error bars (sometimes smaller than the symbols) indicate the standard deviations (\(n = 3\)). ●, translocation from the basolateral to the apical compartment; ○, translocation from the apical to the basolateral compartment.
The percentage of the dose that is secreted into the milk in 30 min was estimated assuming that the total milk volume present in the mammary glands at the time of milk collection was 1 to 2 ml. In this case, the values are around 7.5 to 15% for wild-type mice and 0.5 to 1% for Bcrp1<sup>−/−</sup> mice. These results indicate that Bcrp1 plays a major role in the secretion of nitrofurantoin into the milk and that milk can be a major excretory pathway for this drug, even higher than the hepatobiliary excretion (Fig. 3).

Discussion

Our data clearly show that the antibiotic nitrofurantoin is a very good substrate of Bcrp1/BCRP and that mouse Bcrp1 restricts the oral bioavailability of nitrofurantoin. Bcrp1 also has a predominant role in the hepatobiliary excretion of the drug and in its secretion into the milk. Somewhat surprisingly, we did not observe a substantial effect of Bcrp1 on renal nitrofurantoin excretion.

The contribution of Bcrp1 to the hepatobiliary excretion of nitrofurantoin (98%) is remarkable, if we compare it with other Bcrp1 substrates, such as topotecan (75%; Jonker et al., 2000) and PhIP (less than 50%; van Herwaarden et al., 2003). One explanation for the very large effect of Bcrp1 on nitrofurantoin hepatobiliary excretion is that this drug is not a P-glycoprotein or MRP2 substrate (Fig. 1, F and G), whereas PhIP is also an MRP2 substrate in vitro (Dietrich et al., 2001b), and rat Mrp2 plays a role in its hepatobiliary excretion (Dietrich et al., 2001a). Note that in the case of topotecan (a P-glycoprotein substrate), the contribution of Bcrp1 to its hepatobiliary excretion was investigated using the Bcrp1-inhibitor GF120918 in P-glycoprotein knockout mice (Jonker et al., 2000), and the inhibition may not have been complete.

Our data suggest that intestinal Bcrp1 restricts nitrofurantoin oral bioavailability by reducing its intestinal absorption, but this could not be definitively demonstrated, because fecal excretion of unchanged nitrofurantoin was negligible and also not different between wild-type and Bcrp1<sup>−/−</sup> mice. The very small percentage of the dose recovered from feces could be explained by extensive degradation of nitrofurantoin in the intestinal tract, because rapid breakdown of the drug occurs during fecal incubation (Paul et al., 1960). Note that nitroreduction by intestinal flora (together with nitroreduction by body tissues) has a major contribution in the elimination of the drug (Buzard et al., 1961). Active short-lived intermediates are formed, which are further rapidly converted to nonactive molecules (Shahverdi et al., 2003). Furthermore, we cannot exclude the possibility of extensive reabsorption of the nitrofurantoin excreted into the bile (enterohepatic cycle), providing additional opportunity for metabolic degradation.

Our results also suggest that Bcrp1 does not play a substantial role in the urinary excretion of nitrofurantoin. Besides glomerular filtration, other transporters are probably involved in the urinary excretion of nitrofurantoin (Moller and Sheikh, 1983). The percentage of the dose excreted into the urine we found (around 10%) is very low compared with the data in the literature (40–50%; Paul et al., 1960). Note that in the present study, we only detect unchanged nitrofurantoin. However, it was not always clear from other studies whether all the nitrofurantoin detected was unchanged. In rats, approximately 50% of an administered dose of nitrofurantoin was recovered as metabolites in the urine (Braunlich et al., 1978). In addition, it is known that there are species differences with regard to excretion of nitrofurans in the urine (Paul et al., 1960).

Expression of BCRP in the mouse and human lactating mammary gland and the important role of Bcrp1 in the milk secretion of its substrates have recently been demonstrated by our group (Jonker et al., 2005). Our data clearly show that Bcrp1 plays a major role in the secretion of nitrofurantoin into the milk, as indicated by the large difference in milk-to-plasma ratio between wild-type and Bcrp1<sup>−/−</sup> mice (80-fold higher in the wild-type mice). This difference is even higher than the values obtained previously in our group for other substrates such as PhIP or topotecan (28- and 10-fold higher in wild-type mice, respectively) (Jonker et al., 2005). The nitrofurantoin milk-to-plasma ratio for Bcrp1<sup>−/−</sup> mice (0.6 ± 0.1) is similar to the theoretical milk-to-plasma ratio of 0.5 that physicochemical principles would predict (Kari et al., 1997), suggesting that, in the absence of Bcrp1, the only remaining component of the transport is passive diffusion.

Extrapolating our data to humans, the estimated values for the percentage of the dose excreted into the milk in the wild-type mice (7.5–15%) are very close to what has been

![Fig. 2. Plasma concentration versus time curve after oral (A) and i.v. (B) administration of nitrofurantoin (10 mg/kg, p.o., 5 mg/kg, i.v.) to wild-type (○) and Bcrp1<sup>−/−</sup> (●) mice. Plasma samples were taken during 120 (A) or 60 min (B). Plasma levels of nitrofurantoin were determined by HPLC. Results are the means; error bars indicate S.D. (n = 3–6; *, p < 0.05; **, p < 0.01).](https://example.com/f2.png)
Bcrp1 Affects Disposition of the Antibiotic Nitrofurantoin

estimated in humans. Gerk et al. (2001a) estimated that a breastfed infant would consume 0.2 mg/kg (6% of the maternal dosage) of nitrofurantoin each day. Their study also showed that, in humans, the observed milk-to-serum concentration ratio was 22-fold greater than the one predicted from passive distribution. In the present work, we have shown that nitrofurantoin is effectively transported by human BCRP. It is thus very likely that the same predominant role of Bcrp1 in the milk secretion (and intestinal uptake and hepatobiliary excretion) of nitrofurantoin in mice also applies to human BCRP. Although it has been considered that the 6% of the maternal dose of nitrofurantoin that would be consumed by the infant is a low exposure, it can be of clinical relevance for suckling infants younger than 1 month, with a glucose-6-phosphatase dehydrogenase deficiency or with sensitivity to nitrofurantoin (Gerk et al., 2001a). Note that the effective exposure of the infant could vary as a result of differences in BCRP activity or genetic BCRP polymorphisms (Kondo et al., 2004; Sparreboom et al., 2004), not only in the mother but also in the infant.

Some of the previously reported interactions between nitrofurantoin and other drugs could be explained by competitive inhibition of BCRP-mediated transport. Gerk et al. (2001b) showed that nitrofurantoin reduced milk-to-serum concentration ratios of cimetidine by 33%. Because our group has recently shown that cimetidine is a Bcrp1 substrate and that this transporter also plays a prominent role in its milk secretion (Jonker et al., 2005), it could be that the nitrofurantoin-cimetidine interaction observed is BCRP-mediated.

From the present study, we cannot exclude the presence of additional basolateral transport mechanisms for nitrofurantoin, as has been suggested previously (Gerk et al., 2001b, 2003). Transport in parental MDCK cells even suggests existence of such transporter (Fig. 1A). However, these other transport mechanisms would probably not have a great influence on the exposure to nitrofurantoin, because our data clearly show that Bcrp1 plays a predominant role in the pharmacokinetics, hepatobiliary excretion, and milk secretion of nitrofurantoin. Moreover, the most obvious apical ABC transporters P-glycoprotein and MRP2 do not seem to transport nitrofurantoin. In this perspective, we can consider that nitrofurantoin is an excellent marker drug for BCRP/Bcrp1 activity.

References


Evers R, Koel M, van Deemter L, Janssen H, Calafat J, Oomen LC, Paulusma CC, Oude Eferink RP, Baas F, Schinkel AH, et al. (1998) Drug export activity of the multidrug resistance protein MDR1 and P-glycoprotein ATok sensitivity to nitrofurantoin (Gerk et al., 2001a). Note that the effective exposure of the infant could vary as a result of differences in BCRP activity or genetic BCRP polymorphisms (Kondo et al., 2004; Sparreboom et al., 2004), not only in the mother but also in the infant.

Some of the previously reported interactions between nitrofurantoin and other drugs could be explained by competitive inhibition of BCRP-mediated transport. Gerk et al. (2001b) showed that nitrofurantoin reduced milk-to-serum concentration ratios of cimetidine by 33%. Because our group has recently shown that cimetidine is a Bcrp1 substrate and that this transporter also plays a prominent role in its milk secretion (Jonker et al., 2005), it could be that the nitrofurantoin-cimetidine interaction observed is BCRP-mediated.

From the present study, we cannot exclude the presence of additional basolateral transport mechanisms for nitrofurantoin, as has been suggested previously (Gerk et al., 2001b, 2003). Transport in parental MDCK cells even suggests existence of such transporter (Fig. 1A). However, these other transport mechanisms would probably not have a great influence on the exposure to nitrofurantoin, because our data clearly show that Bcrp1 plays a predominant role in the pharmacokinetics, hepatobiliary excretion, and milk secretion of nitrofurantoin. Moreover, the most obvious apical ABC transporters P-glycoprotein and MRP2 do not seem to transport nitrofurantoin. In this perspective, we can consider that nitrofurantoin is an excellent marker drug for BCRP/Bcrp1 activity.

References


Address correspondence to: Dr. Alfred H. Schinkel, Division of Experimental Therapy, The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands. E-mail: a.schinkel@nki.nl